[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100643497":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":15,"locations":21,"responsibleParty":36,"collaborators":10,"id":40,"slug":41,"hasResults":42,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":10,"eligibilityCriteria":46,"healthyVolunteers":47,"sex":48,"minAge":49,"maxAge":10,"enrollmentInfo":50,"targetDuration":10,"studyType":53,"phases":10,"briefSummary":54,"conditions":55,"keywords":10,"overallStatus":23,"whyStopped":10,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},{"fullName":5,"class":6},"Seoul National University Hospital","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"SLE patients",null,"Patients with SLE",{"label":13,"type":10,"description":14,"interventionNames":10},"Control subjects","Subjects without autoimmune diseases",[16],{"name":17,"role":18,"phone":19,"phoneExt":10,"email":20},"Jin Kyun Park, MD","CONTACT","82-2-2072-4765","jinkyunpark@snu.ac.kr",[22],{"facility":5,"status":23,"city":24,"state":10,"zip":25,"country":26,"countryCode":10,"cosmosGeoPoint":27,"geoPoint":32,"contacts":33},"RECRUITING","Seoul","03080","South Korea",{"type":28,"coordinates":29},"Point",[30,31],126.9784,37.566,{"lat":31,"lon":30},[34],{"name":17,"role":18,"phone":19,"phoneExt":10,"email":35},"jinkyunpark@gmail.com",{"type":37,"investigatorFullName":38,"investigatorTitle":39,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Eun Bong Lee","Professor","100643497","reduced-vaccine-response-to-hzsu-in-sle-100643497",false,"NCT07636044","Reduced Vaccine Response to HZ\u002Fsu in SLE","Reduced Cell-mediated Immune Response to 2 Doses of an Adjuvanted Herpes Zoster Subunit Vaccine in Patients With Systemic Lupus Erythematosus","Inclusion Criteria:\n\n* Males or females ≥ 50 years of age at time of consent\n* ≥ 4 of the 1997 ACR13 or the 2012 SLICC\u002FACR criteria for SLE (14, 15)\n* Clinically stable SLE\n* Stable dose of one or more of the following immunosuppressive treatment ≥ 4 weeks\n* Corticosteroid use: ≥ 5mg\u002Fday of prednisolone equivalent\n* Antimalarials (≤ 400 mg\u002Fday)\n* Azathioprine (≤ 3 mg\u002Fkg\u002Fday)\n* Mycophenolate mofetil (≤ 3 mg\u002Fday)\n* Tacrolimus (≤ 5mg\u002Fday)\n* Methotrexate (≤ 20mg\u002Fweek)\n* Cyclosphosphamide (≤ 1mg\u002FBSA\u002Fmonth)\n* Must be eligible for the indication of adjuvanted herpes zoster subunit vaccine\n* Must understand and voluntarily sign an informed consent form including writing consent for data protection\n\nExclusion Criteria:\n\n* Pregnant or lactating females\n* Acute infection with temperature \\>38C at the time of vaccination\n* Previous anaphylactic response to vaccine components or to egg\n* History of Guillain-Barre syndrome or demyelinating syndromes\n* Any condition including laboratory abnormality which places the subject at unacceptable risk\n* Subjects who decline to participate",true,"ALL","50 Years",{"count":51,"type":52},80,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to compare the vaccine response to the 2 doses of the adjuvanted herpes zoster subunit vaccine(HZ\u002Fsu, \"Shingrix\") in patients with SLE and the age-, sex-, ethnicity-matched controls without autoimmune disease.",[56,57,58],"Vaccine Reaction","Zoster","Systemic Lupus Erythematosus","2026-06-04",{"date":61,"type":62},"2026-06-09","ACTUAL",{"date":64,"type":62},"2024-10-01",{"date":66,"type":52},"2030-10-01",{"name":5,"class":6},1]